Andrew Tsai
Stock Analyst at Jefferies
(1.54)
# 2,284
Out of 4,415 analysts
13
Total ratings
50%
Success rate
12.7%
Average return
Main Sectors:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUSN Fusion Pharmaceuticals | Downgrades: Hold | $10 → $21 | $21.45 | -2.10% | 1 | Mar 19, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $14.22 | +132.07% | 1 | Feb 27, 2024 | |
| VTGN VistaGen Therapeutics | Upgrades: Buy | $0.2 → $15 | $4.50 | +233.33% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $1.74 | +72.41% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $1.96 | +53.06% | 1 | Jun 23, 2022 | |
| BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $17.47 | -8.41% | 1 | Mar 16, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $3.03 | +560.07% | 1 | Feb 1, 2022 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | n/a | $68.80 | - | 1 | Sep 20, 2021 | |
| ATAI Atai Life Sciences | Initiates: Buy | n/a | $2.05 | - | 1 | Sep 1, 2021 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Buy | n/a | $42.55 | - | 1 | Nov 23, 2020 | |
| XENE Xenon Pharmaceuticals | Assumes: Buy | n/a | $43.00 | - | 1 | Jun 1, 2020 | |
| RLMD Relmada Therapeutics | Initiates: Buy | n/a | $3.68 | - | 1 | Jan 27, 2020 |
Fusion Pharmaceuticals
Mar 19, 2024
Downgrades: Hold
Price Target: $10 → $21
Current: $21.45
Upside: -2.10%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $14.22
Upside: +132.07%
VistaGen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $4.50
Upside: +233.33%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.74
Upside: +72.41%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $1.96
Upside: +53.06%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $17.47
Upside: -8.41%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $3.03
Upside: +560.07%
Intra-Cellular Therapies
Sep 20, 2021
Maintains: Buy
Price Target: n/a
Current: $68.80
Upside: -
Atai Life Sciences
Sep 1, 2021
Initiates: Buy
Price Target: n/a
Current: $2.05
Upside: -
Cerevel Therapeutics Holdings
Nov 23, 2020
Initiates: Buy
Price Target: n/a
Current: $42.55
Upside: -
Xenon Pharmaceuticals
Jun 1, 2020
Assumes: Buy
Price Target: n/a
Current: $43.00
Upside: -
Relmada Therapeutics
Jan 27, 2020
Initiates: Buy
Price Target: n/a
Current: $3.68
Upside: -